Cinti, Francesca
Leccisotti, Lucia
Sorice, Gian Pio
Capece, Umberto
D’Amario, Domenico
Lorusso, Margherita
Gugliandolo, Shawn
Morciano, Cassandra
Guarneri, Andrea
Guzzardi, Maria Angela
Mezza, Teresa
Capotosti, Amedeo
Indovina, Luca
Ferraro, Pietro Manuel
Iozzo, Patricia
Crea, Filippo
Giordano, Alessandro
Giaccari, Andrea
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of Dapagliflozin on Myocardial Insulin Sensitivity and Perfusion: Rationale and Design of The DAPAHEART Trial
https://0-doi-org.brum.beds.ac.uk/10.1007/s13300-021-01083-1
Dapagliflozin treatment is associated with a reduction of epicardial adipose tissue thickness and epicardial glucose uptake in human type 2 diabetes
https://0-doi-org.brum.beds.ac.uk/10.1186/s12933-023-02091-0
Article History
Received: 10 October 2023
Accepted: 11 December 2023
First Online: 19 December 2023
Declarations
:
: The study was approved by the local ethics committee (Fondazione Policlinico Universitario Agostino Gemelli IRCCS, study protocol code GIA-DAP-16–005) and registered at eudract.ema.europa.eu (EudraCT No. 2016-003614-27) and ClinicalTrials.gov (NCT 03313752). Informed, written consent was obtained from all participants.
: The corresponding author certifies the accuracy of the content, in particular, that the names of coauthors and addresses and affiliations are up to date. The corresponding author certifies that all the co-authors have agreed to all the contents and will notify all the authors when the manuscript is accepted. The corresponding author certifies that all authors have seen and approved the final version of the paper, and all are aware of the submission of the paper. All authors consent to publication.
: None of the authors have any competing interests in the manuscript.